NO-13065

NO-13065 is an investigational small molecule drug being developed by Otsuka Pharmaceutical Factory for the treatment of obesity. It is a new molecular entity with a novel mechanism of action that targets lipoprotein lipase in skeletal muscle, aiming to increase energy consumption rather than suppress appetite. The detailed mechanism is still under investigation, but it represents a mechanistically distinct approach from GLP-1 receptor agonists and other anti-obesity drugs. Early clinical development (Phase 1) has focused on evaluating safety, tolerability, pharmacokinetics, and food effects in healthy and obese adults[1][3][5][10].